FAIRLAWN, Ohio (July 31)—Apex Medical Technologies Inc. has signed one partially exclusive contract with a company overseas and is in active negotiations with another firm for use of Apex Medical's proprietary curing system. The company also is planning to expand its exclusive curing technology to silicone, Mark McGlothlin, Apex president and CEO, said July 30 at the International Latex Conference in Fairlawn, outside of Akron. The deal with the unnamed overseas business is exclusive for the Japanese market but non-exclusive for the rest of the world, McGlothlin said. The contract gives the firm the right to use the curing technology for polyisoprene latex condoms. Apex Medical's curing system reduces latex cure times and eliminates the need for prevulcanization and maturation. Properties such as tensile set, solvent resistance and high-temperature stability are improved with post-dip crosslinking of both solvent- and water-based polyurethanes, the executive said. In addition, zinc oxide, sulfer, boosters and accelerators are unnecessary with the system. The second company considering a contract for the curing system also was unidentified. If the deal is completed, it will use the curing technology on polyisoprene surgical gloves.